Jiro Miyamae

Dr. Jiro Miyamae


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2023 in Cells
Verified
Journal Article
Open access
PDF file
JMJiro Miyamae
Jiro Miyamae
MOMasaharu Okano
Masaharu Okano
FKFumihiko Katakura
Fumihiko Katakura
Jerzy Kazimierz KulskiJerzy Kazimierz Kulski
Jerzy Kazimierz Kulski
TMTadaaki Moritomo
Tadaaki Moritomo
Takashi ShiinaTakashi Shiina
Takashi Shiina
Polymorphisms of canine leukocyte antigen (DLA) class I (DLA-88 and DLA-12/88L) and class II (DLA-DRB1) genes are important for disease susceptibility studies, but information on the genetic diversity among dog breeds is still lacking. To better elucidate the polymorphism and genetic diversity between breeds, we genotyped DLA-88, DLA-12/88L, and DLA-DRB1 loci using 829 dogs of 59 breeds in Japan. Genotyping by Sanger sequencing identified 89, 43, and 61 alleles in DLA-88, DLA-12/88L, and DLA-DRB1 loci, respectively, and a total of 131 DLA-88–DLA-12/88L–DLA-DRB1 haplotypes (88-12/88L-DRB1) were detected more than once. Of the 829 dogs, 198 were homozygotes for one of the 52 different 88-12/88L-DRB1 haplotypes (homozygosity rate: 23.8%). Statistical modeling suggests that 90% of the DLA homozygotes or heterozygotes with one or other of the 52 different 88-12/88L-DRB1 haplotypes within somatic stem cell lines would benefit graft outcome after 88-12/88L-DRB1-matched transplantation. As previously reported for DLA class II haplotypes, the diversity of 88-12/88L-DRB1 haplotypes varied remarkably between breeds but was relatively conserved within most breeds. Therefore, the genetic characteristics of high DLA homozygosity rate and poor DLA diversity within a breed are useful for transplantation therapy, but they may affect biological fitness as homozygosity progresses.

12 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JMJiro Miyamae
Jiro Miyamae
KMKohei Murakami
Kohei Murakami
HHHiroaki Hemmi
Hiroaki Hemmi
Characterization of naturally processed MHC class I (MHC-I)-bound peptides is essential for defining allele-specific peptide-binding features and understanding the functional consequences of MHC-I polymorphism. However, immunopeptidome analyses of dog leukocyte antigen (DLA) class I (DLA-I) molecules remain limited and comprehensive monoallelic ligand datasets for prevalent DLA-88 alleles are still lacking. Here, we established canine melanoma-derived cell populations expressing individual functional DLA-88 alleles and generated a monoallelic immunopeptidome atlas of prevalent DLA-88 alleles. Using liquid chromatography-tandem mass spectrometry, we identified 32,702 naturally processed peptides of 7–15 amino acids across 10 DLA-88 alleles, substantially expanding the available DLA-88 immunopeptidome landscape. These 10 alleles exhibited canonical peptide length distributions and allele-specific binding motifs that reflected variation in binding-groove pseudo-sequences defined from human MHC-I peptide-contact residues. Ligand sharing between DLA-88 alleles was associated with binding site distance. Incorporation of the comprehensively characterized DLA-88 ligand datasets in this study increased by more than fourfold the number of published canine DLA-I alleles with ligand-characterized reference alleles predicted to have similar peptide-binding features. We also found that antigen-processing signatures were highly conserved with those reported in humans. As a proof-of-concept application, we selected 54 DLA-88-bound peptides identified in our immunopeptidome analysis as candidate peptides for canine cancer immunotherapy by evaluating the normal tissue expression profiles of their source proteins. This DLA-88 immunopeptidome atlas provides insights into allele-dependent differences in antigen presentation and represents a valuable resource for developing accurate DLA-88-binding peptide prediction tools and supporting peptide-based immunological studies in dogs.